Product Information
SUMATRIPTAN 6 MG/0.5 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $15.0000 per ML under NDC 63323027301. Its NADAC has been published 109 times since Apr 23, 2014.
FDA first approved this application on Mar 2, 2009. Its Orange Book therapeutic-equivalence code is AP.
Strength
6 mg/.5mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323027301
Classification
Generic
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
7/22/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA079242FDA Approved
3/2/2009
TE Code
AP
On Market Since
4/12/2011
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN 6 MG/0.5 ML VIAL has been published 109 times since Apr 23, 2014, and over the history we have for it it has declined 85.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.0000 per ML |
|---|---|
| All-time high | $105.0240 (Jun 3, 2015) |
| All-time low | $14.4040 (Oct 22, 2025) |
| 52-week high | $15.0000 |
| 52-week low | $14.4040 |
| Median price | $105.0240 |
| Average price | $63.6712 |
| Largest weekly change | -86.3% (Oct 22, 2025) |
| Weeks tracked | 109 |
| Tracking since | Apr 23, 2014 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sumatriptan Succinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN 6 MG/0.5 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN 6 MG/0.5 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $15.0000 per ML (NDC 63323027301), effective Sep 30, 2026.
How has the price of SUMATRIPTAN 6 MG/0.5 ML VIAL changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN 6 MG/0.5 ML VIAL has declined 85.7%. It has been tracked across 109 weekly CMS publications since Apr 23, 2014.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN 6 MG/0.5 ML VIAL?
Since Apr 23, 2014, the NADAC for SUMATRIPTAN 6 MG/0.5 ML VIAL has ranged from a low of $14.4040 (Oct 22, 2025) to a high of $105.0240 (Jun 3, 2015), with a median of $105.0240 per ML.
Are there cheaper alternatives to SUMATRIPTAN 6 MG/0.5 ML VIAL?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as SUMATRIPTAN 6 MG/0.5 ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures SUMATRIPTAN 6 MG/0.5 ML VIAL?
SUMATRIPTAN 6 MG/0.5 ML VIAL (NDC 63323027301) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.